The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis

SIMPLE SUMMARY: Tucatinib is recommended by different guidelines as a third line of treatment in HER2(+) breast cancer. Although it is an effective treatment, different studies have highlighted that the high price of the drug makes it a not cost-effective treatment option. Therefore, this study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonazzo, Ippazio Cosimo, Cortesi, Paolo Angelo, Miceli Sopo, Gerardo, Mazzaglia, Giampiero, Conte, Pierfranco, Mantovani, Lorenzo Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953803/
https://www.ncbi.nlm.nih.gov/pubmed/36831518
http://dx.doi.org/10.3390/cancers15041175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953803/
https://www.ncbi.nlm.nih.gov/pubmed/36831518
http://dx.doi.org/10.3390/cancers15041175

Ejemplares similares